Last reviewed: June 24, 2026
Last updated: June 24, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
When type 2 diabetes becomes harder to control with single medications, doctors often recommend combining insulin with GLP-1 receptor agonists—a strategy supported by major clinical guidelines. This combination addresses two different pathways in glucose regulation, making it effective for people who haven't reached target blood sugar levels on insulin alone. Understanding how these medications work together helps patients make informed decisions about their diabetes management plan.
How Insulin and GLP-1 Medications Work Together
Insulin works by replacing or supplementing the body's natural insulin production, allowing cells to absorb glucose from the bloodstream. GLP-1 receptor agonists like semaglutide and tirzepatide operate through a completely different mechanism—they slow stomach emptying, reduce appetite, and signal the pancreas to release insulin only when blood sugar rises. Because these medications address separate biological pathways, combining them often produces better blood sugar control than either drug alone.
Research shows that patients using both insulin and GLP-1 medications experience greater reductions in hemoglobin A1c (a marker of long-term blood sugar control) compared to insulin monotherapy. A landmark trial published in Diabetes Care demonstrated that adding GLP-1 therapy to insulin-treated patients lowered A1c by an additional 0.5–1.0 percentage points while reducing body weight. This dual-pathway approach is particularly valuable for people with longer diabetes duration or significant insulin resistance.
Clinical Evidence for Combination Insulin and GLP-1 Therapy
Major diabetes organizations including the American Diabetes Association recognize insulin plus GLP-1 combination therapy as a standard treatment option for people who haven't met glycemic targets on insulin alone. Clinical trials consistently show that this pairing reduces both fasting and postprandial (after-meal) blood glucose levels more effectively than stepping up insulin doses alone. Studies also document weight loss benefits—patients typically lose 2–4 kilograms beyond what insulin monotherapy achieves.
Cardiovascular benefits add another layer of evidence supporting combination therapy. Several large trials have shown that GLP-1 receptor agonists reduce the risk of heart attack and stroke in people with type 2 diabetes, benefits that persist even when used alongside insulin. This means patients gain blood sugar control, weight loss, and heart protection simultaneously—a compelling rationale for many specialists to recommend combination approaches early in treatment escalation.
Personalized GLP-1 Selection: GLP-Squared for Dual Benefits
PlexusDx offers GLP-Squared injection—a dual-compound formulation combining semaglutide and tirzepatide in a single monthly injection. This product starts at $249/month and allows patients already committed to insulin therapy to add comprehensive GLP-1 benefit without managing multiple injections or prescriptions. Because both compounds are sourced from licensed 503A compounding pharmacies, PlexusDx ensures pharmaceutical-grade quality while keeping costs accessible.
The choice between semaglutide and tirzepatide (or the combined GLP-Squared option) depends on individual factors like metabolic health, kidney function, and genetic predisposition to peptide pathway responsiveness. PlexusDx's Precision Peptide Genetic Test ($99 add-on after first month) maps 14 metabolic pathways and 49 peptide-related genes—including variants in GLP1R, GIPR, FTO, and MC4R—to help identify which GLP-1 compound may work best for your insulin-treated diabetes. This personalization removes guesswork and optimizes therapy from the start.
Safety Considerations When Combining Insulin and GLP-1
One important safety consideration is hypoglycemia risk. When GLP-1 medications stimulate insulin release and also slow digestion, the combined effect can sometimes lower blood sugar too aggressively—especially if insulin doses aren't adjusted downward. Patients using both therapies typically require more frequent blood sugar monitoring and closer communication with their provider to ensure doses remain balanced. Many specialists reduce basal (long-acting) insulin doses by 15–20% when initiating GLP-1 therapy to prevent low blood sugar episodes.
Gastrointestinal side effects are common when starting GLP-1 medications, particularly nausea, constipation, or reduced appetite. These effects usually diminish within 2–4 weeks but are more pronounced during dose escalation. Since insulin injections continue independently, patients need a clear schedule for titrating the GLP-1 component while maintaining stable insulin regimens. PlexusDx medication plans include detailed dosing timelines and side-effect expectations to help patients navigate this adjustment phase successfully.
Access and Cost: Insulin Plus GLP-1 Made Affordable
Unlike traditional insulin pens or pump supplies, GLP-1 therapy through PlexusDx requires no insurance, no membership fees, and works with HSA and FSA accounts. Monthly pricing for compounded semaglutide, tirzepatide, or GLP-Squared remains flat—your dose may need to go up as you progress through treatment, but your price won't increase. Starting at $249 per month for GLP-Squared injection, patients gain access to dual-compound therapy without navigating insurance authorization delays or formulary restrictions.
PlexusDx serves all 50 states and ships medications directly to patients, making combination insulin-plus-GLP-1 therapy logistically simple. Because compounded medications are prepared fresh by licensed pharmacies, they often cost significantly less than brand-name equivalents while maintaining strict quality standards. For patients already paying out-of-pocket for insulin, adding an affordable GLP-1 option through PlexusDx removes financial barriers to achieving better diabetes control and weight management outcomes.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Glp Squared starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Can I use insulin and GLP-1 medications at the same time?
Yes. Combining insulin with GLP-1 receptor agonists is a standard, evidence-based approach recommended by major diabetes organizations for people whose blood sugar remains elevated on insulin alone. The two medications work through different mechanisms, so combining them often provides superior blood sugar and weight-loss results compared to either therapy alone.
Does adding GLP-1 therapy to insulin reduce hypoglycemia risk?
While GLP-1 medications improve overall blood sugar control, they can increase hypoglycemia (low blood sugar) risk if insulin doses aren't adjusted downward. Most specialists reduce basal insulin by 15–20% when starting GLP-1 therapy and monitor blood glucose more frequently during the adjustment period. Close communication with your healthcare provider is essential to balance both medications safely.
What is GLP-Squared and how does it fit into insulin-based diabetes management?
GLP-Squared is PlexusDx's dual-compound injection combining semaglutide and tirzepatide, starting at $249 per month. It allows insulin-treated patients to add comprehensive GLP-1 benefit in a single monthly injection, simplifying medication regimens and reducing injection burden while maintaining flat pricing regardless of dose adjustments.
How long does it take to see weight-loss results when combining insulin and GLP-1?
Weight loss from GLP-1 therapy typically becomes noticeable within 4–8 weeks, with more significant results accumulating over 3–6 months as doses are gradually increased. Combined insulin-and-GLP-1 therapy often produces weight loss of 2–4 additional kilograms beyond what insulin monotherapy achieves, though individual results vary based on diet, activity, and genetic factors.
Can the Precision Peptide Genetic Test help me choose between semaglutide and tirzepatide?
Yes. PlexusDx's Precision Peptide Genetic Test ($99 add-on) analyzes 49 peptide-pathway genes including GLP1R, GIPR, FTO, and MC4R variants to identify which GLP-1 compound may work best for your metabolism. This genetic insight removes guesswork when deciding between semaglutide, tirzepatide, or GLP-Squared alongside your insulin regimen.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Optimizing Your Weight Loss Journey: Understanding When and Why You Can’t Increase Your Wegovy Dose Early
Optimizing Your Wegovy Journey: What’s the Best Time to Take Wegovy?